The Manufacturers Life Insurance Company Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

The Manufacturers Life Insurance Company acquired a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, Holdings Channel reports. The fund acquired 119,516 shares of the biotechnology company’s stock, valued at approximately $1,195,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $238,930,000. RA Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. grew its position in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the period. Janus Henderson Group PLC increased its stake in BioCryst Pharmaceuticals by 7,807.2% during the 4th quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock valued at $57,791,000 after purchasing an additional 7,310,745 shares in the last quarter. Finally, Perceptive Advisors LLC increased its stake in BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after purchasing an additional 4,271,504 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 1.3%

BioCryst Pharmaceuticals stock opened at $9.96 on Friday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.22. The company’s 50 day moving average price is $9.75 and its two-hundred day moving average price is $9.17. The stock has a market cap of $2.55 billion, a P/E ratio of -6.64 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.15 earnings per share. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wedbush decreased their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They issued a “neutral” rating and a $12.00 target price on the stock. Cantor Fitzgerald raised their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Finally, Royal Bank Of Canada cut their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.